RESEARCH TRIANGLE PARK, N.C., March 2, 2026
IQVIA Holdings Inc. (NYSE: IQV) announced that Chairman and Chief Executive Officer Ari Bousbib will speak at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, at 9:20 a.m. ET, reinforcing the company’s leadership position in clinical research services, healthcare intelligence, and AI-driven life sciences solutions. The live webcast of the presentation will be available via the company’s Investor Relations platform, reflecting IQVIA’s continued engagement with global healthcare investors and stakeholders.
Strategic Focus on Clinical Research and AI Innovation
As a leading global provider of clinical research services, commercial insights, and healthcare analytics, IQVIA plays a central role in supporting pharmaceutical, biotechnology, and medical device companies throughout the drug development lifecycle. The company’s technology ecosystem is powered by IQVIA Connected Intelligence™, integrating high-quality health data, advanced analytics, and Healthcare-grade AI® to accelerate development timelines and improve commercialization strategies. With approximately 93,000 employees across more than 100 countries, IQVIA combines domain expertise in data science, regulatory compliance, and operational execution to deliver scalable solutions that address evolving global healthcare demands.
The upcoming conference presentation is expected to highlight IQVIA’s strategic growth priorities, including expansion of AI-powered analytics, strengthening of privacy-enhancing technologies, and enhanced regulatory-grade data capabilities. In an increasingly data-driven pharmaceutical landscape, the integration of real-world evidence, AI-enabled insights, and patient-centric data platforms is becoming critical for sponsors seeking efficient clinical trial design and market access optimization.
Advancing Responsible AI in Healthcare
Advertisement
A core differentiator for IQVIA lies in its commitment to responsible AI deployment built on best-in-class standards for privacy, regulatory compliance, and patient safety. The company emphasizes scalable AI systems designed to meet the high precision and trust requirements of the life sciences industry. As global regulators increase scrutiny over data governance and artificial intelligence in healthcare applications, IQVIA’s privacy-enhancing technologies and compliance-focused frameworks position it as a strategic partner for biopharma and medtech innovators.
IQVIA’s solutions enable pharmaceutical and biotech companies to identify disease patterns, correlate treatment pathways, and optimize clinical development programs through integrated intelligence platforms. By combining AI-driven analytics with extensive healthcare datasets, the company supports faster evidence generation and more informed decision-making across R&D and commercialization pipelines.
Strengthening Industry and Investor Engagement
Participation in the Leerink Partners 2026 Global Healthcare Conference underscores IQVIA’s continued visibility among healthcare-focused institutional investors and industry analysts. The event serves as a strategic forum for discussing innovation trends in biopharma services, digital health transformation, and healthcare data intelligence. As demand rises for integrated contract research and technology-enabled services, IQVIA remains positioned at the intersection of clinical trial operations, regulatory-grade analytics, and AI innovation.
With the healthcare sector increasingly reliant on data integrity, real-world insights, and predictive analytics, IQVIA’s expanding capabilities reinforce its role as a global leader in clinical research optimization and healthcare intelligence solutions. The March 9 presentation is anticipated to provide further clarity on the company’s long-term strategy, competitive differentiation, and commitment to accelerating the development and commercialization of innovative medical treatments worldwide.
Source: IQVIA press release
